vs
奇富科技（QFIN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是奇富科技的1.1倍（$772.1M vs $731.2M），奇富科技净利率更高（27.5% vs 12.7%，领先14.8%），过去两年奇富科技的营收复合增速更高（16.4% vs 9.0%）
奇富科技（原360数科）是中国头部金融科技企业，主要为持牌金融机构提供智能风控、信贷技术解决方案，服务广大个人消费者及中小微企业，依托大数据、人工智能技术提升金融服务的普惠性与运营效率。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
QFIN vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$731.2M
净利率更高
QFIN
高出14.8%
12.7%
两年增速更快
QFIN
近两年复合增速
9.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $731.2M | $772.1M |
| 净利润 | $201.2M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 32.7% | 14.5% |
| 净利率 | 27.5% | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QFINRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $731.2M | $698.9M | ||
| Q2 25 | $728.1M | $720.3M | ||
| Q1 25 | $646.4M | $664.8M | ||
| Q4 24 | — | $729.4M | ||
| Q3 24 | $622.7M | $684.0M | ||
| Q2 24 | $572.4M | $691.7M | ||
| Q1 24 | $575.2M | $649.9M |
净利润QFINRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $201.2M | $46.7M | ||
| Q2 25 | $241.6M | $53.9M | ||
| Q1 25 | $247.6M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $256.3M | $94.4M | ||
| Q2 24 | $189.4M | $55.4M | ||
| Q1 24 | $160.7M | $26.0M |
毛利率QFINRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率QFINRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 32.7% | 11.7% | ||
| Q2 25 | 41.0% | 12.6% | ||
| Q1 25 | 42.1% | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | 52.4% | 14.3% | ||
| Q2 24 | 47.7% | 12.4% | ||
| Q1 24 | 32.8% | 6.8% |
净利率QFINRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 27.5% | 6.7% | ||
| Q2 25 | 33.2% | 7.5% | ||
| Q1 25 | 38.3% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 41.2% | 13.8% | ||
| Q2 24 | 33.1% | 8.0% | ||
| Q1 24 | 27.9% | 4.0% |
每股收益（稀释后）QFINRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.5B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $24.3B | $7.3B |
| 总资产 | $61.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资QFINRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $6.5B | $931.4M | ||
| Q2 25 | $5.3B | $991.8M | ||
| Q1 25 | $8.6B | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $4.3B | $1.2B | ||
| Q2 24 | $6.3B | $2.0B | ||
| Q1 24 | $5.3B | $1.7B |
股东权益QFINRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $24.3B | $7.4B | ||
| Q2 25 | $24.1B | $7.6B | ||
| Q1 25 | $23.1B | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | $22.9B | $7.9B | ||
| Q2 24 | $22.6B | $7.9B | ||
| Q1 24 | $22.1B | $7.8B |
总资产QFINRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $61.4B | $12.1B | ||
| Q2 25 | $59.8B | $12.4B | ||
| Q1 25 | $55.6B | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | $47.0B | $12.8B | ||
| Q2 24 | $47.0B | $13.4B | ||
| Q1 24 | $47.4B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $351.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.75× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流QFINRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $351.4M | $138.5M | ||
| Q2 25 | $366.0M | $134.3M | ||
| Q1 25 | $386.6M | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | $338.0M | $147.9M | ||
| Q2 24 | $269.9M | $158.6M | ||
| Q1 24 | $271.2M | $147.6M |
自由现金流QFINRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率QFINRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度QFINRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率QFINRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 1.75× | 2.97× | ||
| Q2 25 | 1.52× | 2.49× | ||
| Q1 25 | 1.56× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 1.32× | 1.57× | ||
| Q2 24 | 1.43× | 2.87× | ||
| Q1 24 | 1.69× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QFIN
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
